Introduction {#sec1_1}
============

Worldwide, Alzheimer disease (AD) is the most common form of dementia in elderly persons \[[@B1]\]. It is a neurodegenerative disorder that typically demonstrates an insidious initial impairment in memory that extends to multiple domains such as language, certain visuospatial abilities, and executive functions as the disease progresses \[[@B2], [@B3], [@B4]\]. Mild cognitive impairment (MCI) is a cognitive state that demonstrates measurable memory deficits between normal aging and early dementia, and a substantial part of MCI - especially the amnestic subtype of MCI - is considered a prodrome of AD \[[@B5], [@B6], [@B7]\]. The early detection of dementia is important for emerging treatment possibilities and the early initiation of care, so current research has paid considerable attention to the identification of MCI and early AD.

Because episodic memory - defined as the recollection of specific past events or information - is the first and most severely affected domain in patients with AD and MCI \[[@B8], [@B9]\], memory tests have been used in memory clinics and diagnostic centers as the first stage of screening for these conditions. Among memory tests, the Logical Memory-delayed recall subtest (LMT) of the Wechsler Memory Scale is regarded as a simple and useful screening tool with high sensitivity and specificity for differentiating normal elderly individuals from patients with AD or MCI \[[@B10], [@B11], [@B12]\]. Although the LMT is one of the strongest tests in predicting conversion from MCI to AD, it also has a significant role in distinguishing early and late stages of MCI \[[@B13], [@B14]\]. The Scenery Picture Memory Test (SPMT) is a recently developed memory test, and a proven and very useful tool for detecting mild and very mild AD \[[@B15]\].

Longitudinal studies are crucial for better understanding the progression of dementia syndromes as well as detecting the effects of pharmacological treatment and supporting the lives of patients by estimating subtle changes in performance. Little is known, however, about which psychological tests are useful for detecting changes in the cognition of patients with MCI and mild AD. Therefore, in this study, we aimed to measure the average annual rates of decline in Mini-Mental State Examination (MMSE), LMT, SPMT, and other cognitive screening test scores.

Subjects and Methods {#sec1_2}
====================

Participants {#sec2_1}
------------

We recruited a group of 33 patients consisting of mild AD patients (*n* = 22) and MCI patients (*n* = 11), and all were followed up for 2 years. The participants were outpatient referrals to the memory clinic of the Department of Neurology at Kyoto University Hospital. All patients underwent head computed tomography or magnetic resonance imaging, as well as a battery of laboratory tests including determination of thyroid function and vitamin B~12~, folate, and serum calcium concentration levels. A diagnosis of AD was made according to the criteria of the 4th edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) and the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer\'s Disease and Related Disorders Association \[[@B16]\]. A diagnosis of MCI was made according to the criteria by Petersen et al. \[[@B5]\]. LMT Alzheimer\'s Disease Neuroimaging Initiative (ADNI) criteria were used to judge the memory disturbance of MCI patients. The patients were initially evaluated as part of their diagnosis before treatment with cholinesterase inhibitors. An annual longitudinal follow-up was performed at 1 and 2 years. There were MCI patients who converted to AD during follow-up; we show the longitudinal cognitive test results of the MCI group according to the initial diagnosis. All patients were \>60 years of age and were administered cholinesterase inhibitors such as donepezil, rivastigmine, or galantamine, except for 2 patients. We prescribed cholinesterase inhibitors when MCI patients requested to take them.

The exclusion criteria used in the present study were depression, dementia with Lewy bodies, cerebrovascular disease, or any other psychological disorder. This study was performed according to the ethical guidelines for biomedical research involving human subjects set by Kyoto University, and written informed consent was obtained from all participants.

Brief Cognitive Screening Tests {#sec2_2}
-------------------------------

Cognitive functions were assessed using the MMSE, LMT, SPMT, Clock-Drawing Test (CDT), Block Design Test (BDT) of the Wechsler Adult Intelligent Scale-Revised (WAIS-R), and Word Fluency Test-vegetable (WFT-V). The MMSE is a global cognitive test that can be used to systematically and thoroughly assess mental status. It is an 11-question measure that tests 5 areas of cognitive function: orientation, registration, attention and calculation, recall, and language. The maximum score is 30 points. A score of ≤23 points is indicative of cognitive impairment \[[@B17]\]. The LMT-story A was only read once to the participants, and what the participants recalled was the immediate recall subtest. The delayed recall subtest was administered ≥30 min after completion of the immediate recall subtest. The SPMT is a short and simple memory test that assesses the visual memory encoded as a scenery in combination with verbal answers. Briefly, the SPMT uses a line drawing of a living room on an A4-sized piece of paper that includes 23 objects that are commonly observed in daily life. The participants were instructed to look at the picture for 1 min and remember the items after an original brief digit forward test (SPMT-I). Then the participants are presented the picture again, and after this second encoding period, we distracted the participants by asking them to perform the digit span test of the WAIS-R. The participants were then asked to recall the objects in the picture without a time limit (SPMT-II). The number of items recalled was the score for the SPMT. Higher scores indicate better cognitive function \[[@B15]\]. For the CDT, the participants were asked to draw a clock with all numbers on a blank piece of paper and indicate the time as 10 min after 11 o\'clock. We used a 10-point scoring system \[[@B18]\]. The BDT required individuals to use 4--16 red- and white-colored blocks to replicate a design presented as an image on a piece of paper. In the WFT-V, the participants were instructed to name as many vegetables as possible in 1 min \[[@B19]\].

Statistical Analyses {#sec2_3}
--------------------

All analyses were conducted using SPSS software (version 20.0; SPSS Inc., Chicago, IL, USA). All statistics were 2-tailed, and statistical significance was set at *p* \< 0.05. The obtained data are presented as the means ± standard deviations for normally distributed variables. The differences between the group means of the continuous variables were analyzed using the Student *t* test.

Results {#sec1_3}
=======

Patient Characteristics {#sec2_4}
-----------------------

Table [1](#T1){ref-type="table"} shows the demographic and clinical data for the MCI and AD groups. Age and years of education did not differ between the MCI and the AD group. As expected, the mean MMSE, SPMT-I, and SPMT-II values were significantly higher in the MCI group than in the AD group (*p* \< 0.01). LMT-immediate recall showed a lower score in the AD group than in the MCI group (*p* \< 0.05), while no significant differences were seen in terms of the LMT-delayed recall, CDT, BDT, or WFT-V scores between the two groups.

Longitudinal Changes {#sec2_5}
--------------------

As shown in Table [2](#T2){ref-type="table"}, for the MCI group a significant decline was observed in SPMT-I score from the initial evaluation (11.2 ± 2.9) to the second year (8.6 ± 4.4), and in SPMT-II score from the initial evaluation (13.4 ± 2.8) to the second year (9.2 ± 5.4). Otherwise, the MMSE, LMT-immediate recall, LMT-delayed recall, CDT, BDT, and WFT-V scores all showed almost no decline from the initial evaluation to the first year, from the first year to the second year, or from the initial evaluation to the second year.

For the AD group, a significant decline was observed in MMSE score from the initial evaluation (24.0 ± 2.9) to the first year (22.9 ± 2.5) and from the initial evaluation (24.0 ± 2.9) to the second year (21.9 ± 2.2). In the SPMT-I score, a significant decline was observed from the initial evaluation (6.8 ± 3.2) to the second year (4.8 ± 3.7) and from the first year (6.1 ± 3.3) to the second year (4.8 ± 3.7). In the SPMT-II score, a significant decline was observed from the initial evaluation (8.1 ± 4.9) to the first year (6.0 ± 4.3), from the first year (6.0 ± 4.3) to the second year (3.5 ± 4.3), and from the initial evaluation (8.1 ± 4.9) to the second year (3.5 ± 4.3). We also observed significant declines in WFT-V score from the first year (10.3 ± 3.3) to the second year (8.8 ± 3.3) and from the initial evaluation (10.7 ± 2.5) to the second year (8.8 ± 3.3). We did not observe any declines in LMT-immediate recall, LMT-delayed recall, CDT, or BDT scores.

Test Score Scatter for the LMT and SPMT Results {#sec2_6}
-----------------------------------------------

To delineate the nature of the changes in scores on the LMT and SPMT, the longitudinal changes in the scores were plotted (Fig. [1](#F1){ref-type="fig"}). MCI and AD are combined in this plot. As shown in this figure, the scores on the LMT were already low even at the initial time of testing. Scores of 0 were frequently observed on the LMT-delayed recall.

Discussion {#sec1_4}
==========

In this study, we performed a longitudinal follow-up over a 2-year period of patients with MCI and AD using the MMSE, LMT, SPMT, CDT, BDT, and WFT-V. By analyzing the changes in these brief cognitive screening tests, we observed that the SPMT can detect cognitive changes more sensitively than the other tests over 2 years. However, the LMT, CDT, and BDT all showed almost no decline in scores. Specifically, LMT-immediate recall and LMT-delayed recall scores neither demonstrated an increase nor lacked a linear downward trend in either group. Although the MMSE and WFT-V could detect longitudinal changes in AD, no significant changes in MCI were observed.

These findings suggest that the SPMT is useful for judging the effects of treatment or for effectively observing longitudinal changes. This effectiveness of the SPMT may come from the "picture superiority effect" that could help memory and avoid the floor effect in patients at this stage \[[@B20], [@B21], [@B22], [@B23]\]. The SPMT is also easy to administer, does not threaten the patient, and takes very little time. SPMT scores showed neither a floor effect nor a ceiling effect in the early stages of cognitive impairment.

As suggested in previous research, the LMT is one of the best-performing tests for discriminating between patients who are healthily aged and patients with mildly dementia \[[@B11], [@B12]\]. AD and MCI patients fail this item because of their episodic memory deficits. As a result, the LMT can detect impairment during an early stage, but we did not see a significant decline because of the floor effect, and this test is excessively difficult to use in the very early stages of dementia. Consequently, the LMT demonstrated a lack of power to detect longitudinal changes in this study.

The MMSE is a widely used screening tool for detecting and evaluating longitudinal changes in dementia patients; however, it has been suggested that it is not appropriate for determining cognitive status during the MCI phase of dementia \[[@B24]\]. Our results demonstrate the weak detection power of the MMSE, not only for detecting but also tracking changes in MCI. Likewise, the WFT-V is a test used to mainly assess frontal lobe function, semantic memory, and language ability, which are injured in moderate AD \[[@B25], [@B26]\], and would demonstrate similar results to the MMSE in this study.

The CDT imposes demands on a wide range of cognitive skills, including auditory attention, semantic knowledge, planning and organization, and visuospatial functions \[[@B27]\]. The BDT also assesses a wide range of cognitive skills, including perceptual and visual organization, abstract thinking, nonverbal concept formation, and visuospatial function. It seems that these tests are not sensitive enough to detect longitudinal changes during the early phase of dementia.

Limitations should be considered when interpreting our results. Our proposed method determines predictions based on longitudinal data, and thus requires each participant to have the corresponding modality data across different time points, which limits the sample size. Further studies using a large sample size would be required to generalize our results. Second, we only used the LMT as the reference memory test in this study. Other potentially useful tests could be taken to determine longitudinal changes in cognition. Therefore, the generalization of our results could be limited. Third, the LMT ADNI criteria were used to judge the memory disturbance of the MCI patients in this study. One may argue that use of the LMT in the diagnosis of MCI may underestimate the role of the LMT during follow-up. However, as the distribution of LMT scores at the initial evaluation indicates, the LMT scores of the participants were apparently lower than the cutoff. This suggests that there were almost no patients who were excluded from the MCI group due to the LMT score.

In conclusion, this study shows that the SPMT is a very useful tool for longitudinal studies on MCI and mild AD. Longitudinal follow-up with the SPMT might be a useful tool for determining the effects of treatment and for effectively observing changes.
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###### 

Demographic and clinical data at the initial evaluation

                               MCI                                          AD
  ---------------------------- -------------------------------------------- ------------
  Patients, *n*                11                                           22
  Sex (male/female), *n*       2/9                                          9/13
  Age, years                   73.7 (5.7)                                   76.7 (6.1)
  Education, years             12.6 (2.4)                                   11.6 (2.8)
  MMSE score                   26.8 (1.8)[\*](#T1F1){ref-type="table-fn"}   24.0 (2.9)
  LMT-immediate recall score   5.7 (3.1)[\*](#T1F1){ref-type="table-fn"}    3.4 (2.3)
  LMT-delayed recall score     2.3 (1.8)                                    1.2 (1.9)
  SPMT-I score                 11.2 (2.9)[\*](#T1F1){ref-type="table-fn"}   6.8 (3.2)
  SPMT-II score                13.4 (2.8)[\*](#T1F1){ref-type="table-fn"}   8.1 (4.9)
  CDT score                    9.3 (1.3)                                    9.1 (1.2)
  BDT score                    27.9 (6.1)                                   21.7 (9.3)
  WFT-V score                  11.3 (3.0)                                   10.7 (2.5)

Data are presented as the mean (SD).

Significantly different between MCI and AD patients. AD, Alzheimer disease; BDT, Block Design Test; CDT, Clock-Drawing Test; LMT, Logical Memory Test; MCI, mild cognitive impairment; MMSE, Mini-Mental State Examination; SPMT, Scenery Picture Memory Test; WFT-V, Word Fluency Test-vegetable.

###### 

Longitudinal changes in brief cognitive screening tests

                               MCI                                          AD
  ---------------------------- -------------------------------------------- ---------------------------------------------------------------------------------
  MMSE score                                                                
   Initial                     26.8 (1.8)                                   24.0 (2.9)
   1st year                    25.7 (2.1)                                   22.9 (2.5)[\*](#T2F1){ref-type="table-fn"}
   2nd year                    24.8 (3.8)                                   21.9 (2.2)[^††^](#T2F4){ref-type="table-fn"}
  LMT-immediate recall score                                                
   Initial                     5.7 (3.1)                                    3.4 (2.3)
   1st year                    5.4 (3.3)                                    3.7 (2.6)
   2nd year                    4.1 (4.0)                                    3.2 (2.6)
  LMT-delayed recall score                                                  
   Initial                     2.3 (1.8)                                    1.2 (1.9)
   1st year                    2.2 (2.9)                                    1.2 (1.9)
   2nd year                    2.1 (3.6)                                    0.8 (2.0)
  SPMT-I score                                                              
   Initial                     11.2 (2.9)                                   6.8 (3.2)
   1st year                    9.8 (3.7)                                    6.1 (3.3)
   2nd year                    8.6 (4.4)[^†^](#T2F3){ref-type="table-fn"}   4.8 (3.7)[^§^](#T2F5){ref-type="table-fn"}, [^†^](#T2F3){ref-type="table-fn"}
  SPMT-II score                                                             
   Initial                     13.4 (2.8)                                   8.1 (4.9)
   1st year                    11.5 (5.5)                                   6.0 (4.3)[\*\*](#T2F2){ref-type="table-fn"}
   2nd year                    9.2 (5.4)[^†^](#T2F3){ref-type="table-fn"}   3.5 (4.3)[^§§^](#T2F6){ref-type="table-fn"}, [^††^](#T2F4){ref-type="table-fn"}
  CDT score                                                                 
   Initial                     9.3 (1.3)                                    9.1 (1.2)
   1st year                    9.4 (0.8)                                    9.0 (1.2)
   2nd year                    8.3 (3.1)                                    8.0 (2.6)
  BDT score                                                                 
   Initial                     27.9 (6.1)                                   21.7 (9.3)
   1st year                    27.6 (7.1)                                   19.9 (8.9)
   2nd year                    25.3 (5.2)                                   19.7 (11.7)
  WFT-V score                                                               
   Initial                     11.3 (3.0)                                   10.7 (2.5)
   1st year                    11.0 (3.2)                                   10.3 (3.3)
   2nd year                    10.6 (3.7)                                   8.8 (3.3)[^§^](#T2F5){ref-type="table-fn"}, [^††^](#T2F4){ref-type="table-fn"}

Data are presented as the mean (SD).

*p* \< 0.05

*p* \< 0.01 (initial evaluation to 1 year)

*p* \< 0.05

*p* \< 0.01 (initial evaluation to 2 years)

*p* \< 0.05

*p* \< 0.01 (1 year to 2 years). AD, Alzheimer disease; BDT, Block Design Test; CDT, Clock-Drawing Test; LMT, Logical Memory Test; MCI, mild cognitive impairment; MMSE, Mini-Mental State Examination; SPMT, Scenery Picture Memory Test; WFT-V, Word Fluency Test-vegetable.
